Zura Bio Limited
NASDAQZura Bio arrives at its August 14 earnings event with an unusually sharp divide between analyst optimism and short-seller conviction — the tension between those two forces is what makes this print matter. The analyst setup is the most striking element heading into the release. Wedbush lifted its target from $15 to $22 on August 12, while Guggenheim moved from $15 to $20 on the same…
Snapshot as of 20 Sept 2026
Zura Bio arrives at its August 14 earnings event with an unusually sharp divide between analyst optimism and short-seller conviction — the tension between those two forces is what makes this print matter. The analyst…
Zura Bio heads into its August 14 earnings event carrying one of the more charged setups in small-cap biotech right now — short interest near a multi-month high, options tilted defensively, and two analysts lifting…
ZURA heads into August earnings with a familiar biotech tension: a stock up 49% over the past month that has spent the last week giving back ground, while short sellers quietly rebuild positions into the rally. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ZURA — free to start on ORTEX.
Sign up for free →Open ZURA on ORTEX